Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gutgesell

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Applied Toxicology : JAT|July 27, 2022
Naphthenic acid fraction components from oil sands process-affected water from the Athabasca Oil Sands Region impair murine osteoblast differentiation and functionRobert M Gutgesell, Laiba Jamshed, Richard A Frank, et al.
Toxicology and Applied Pharmacology|March 8, 2022
The effects of oil sands process-affected water naphthenic acid fraction components on GDF15 secretion in extravillous trophoblast cellsLaiba Jamshed, Genevieve A Perono, Lina R Yacoub, et al.
Journal of Medicinal Chemistry|January 25, 2017
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast CancerRui Xiong, Jiong Zhao, Lauren M Gutgesell, et al.
Plos Biology|April 11, 2025
Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cellsIoanna Oikonomidi, Vasumathi Kameswaran, Victoria C Pham, et al.
Journal of Medicinal Chemistry|May 27, 2020
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and PalbociclibYangfeng Li, Jiong Zhao, Lauren M Gutgesell, et al.
Journal of Medicinal Chemistry|December 19, 2015
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast CancerRui Xiong, Hitisha K Patel, Lauren M Gutgesell, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 21, 2022
The phosphorylation of AMPKβ1 is critical for increasing autophagy and maintaining mitochondrial homeostasis in response to fatty acidsEric M Desjardins, Brennan K Smith, Emily A Day, et al.
Nature Metabolism|July 23, 2020
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight lossEmily A Day, Rebecca J Ford, Brennan K Smith, et al.
Journal of Medicinal Chemistry|November 21, 2019
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast CancerYunlong Lu, Lauren M Gutgesell, Rui Xiong, et al.
Breast Cancer Research and Treatment|March 5, 2020
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancerKaitlyn J Andreano, Suzanne E Wardell, Jennifer G Baker, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Applied Toxicology : JAT|July 27, 2022
Naphthenic acid fraction components from oil sands process-affected water from the Athabasca Oil Sands Region impair murine osteoblast differentiation and functionRobert M Gutgesell, Laiba Jamshed, Richard A Frank, et al.
Toxicology and Applied Pharmacology|March 8, 2022
The effects of oil sands process-affected water naphthenic acid fraction components on GDF15 secretion in extravillous trophoblast cellsLaiba Jamshed, Genevieve A Perono, Lina R Yacoub, et al.
Journal of Medicinal Chemistry|January 25, 2017
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast CancerRui Xiong, Jiong Zhao, Lauren M Gutgesell, et al.
Plos Biology|April 11, 2025
Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cellsIoanna Oikonomidi, Vasumathi Kameswaran, Victoria C Pham, et al.
Journal of Medicinal Chemistry|May 27, 2020
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and PalbociclibYangfeng Li, Jiong Zhao, Lauren M Gutgesell, et al.
Journal of Medicinal Chemistry|December 19, 2015
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast CancerRui Xiong, Hitisha K Patel, Lauren M Gutgesell, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 21, 2022
The phosphorylation of AMPKβ1 is critical for increasing autophagy and maintaining mitochondrial homeostasis in response to fatty acidsEric M Desjardins, Brennan K Smith, Emily A Day, et al.
Nature Metabolism|July 23, 2020
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight lossEmily A Day, Rebecca J Ford, Brennan K Smith, et al.
Journal of Medicinal Chemistry|November 21, 2019
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast CancerYunlong Lu, Lauren M Gutgesell, Rui Xiong, et al.
Breast Cancer Research and Treatment|March 5, 2020
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancerKaitlyn J Andreano, Suzanne E Wardell, Jennifer G Baker, et al.
Pageof 3